



Research on Targeted Drugs in Cancer

Guest Editors:

Dr. Marjorie E. Zettler

Clinical Science, Accutar
Biotechnology Inc., Cranbury, NJ,
USA

Dr. Bertal Aktas

Department of Medicine,
Brigham and Women's Hospital
and Harvard Medical School,
Boston, MA, USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editors

Over the past two decades, the emergence of targeted therapies has transformed the therapeutic landscape for cancer treatment. Unlike conventional chemotherapies, which indiscriminately destroy both malignant and non-malignant cells, targeted therapies are designed to act specifically on cancer cells harboring particular mutations. This revolutionary precision medicine approach has resulted in effective tumor regression with reduced off-target toxicity. Targeted therapies now feature prominently in oncology clinical practice guidelines, and next-generation sequencing to identify actionable mutations has become part of the standard-of-care practice for multiple cancers. Despite this extraordinary progress, resistance to targeted cancer therapies remains a challenge, and continued research to define strategies for preventing and overcoming resistance is warranted.

For this Special Issue of *Cancers*, we are interested in original research and review articles covering a broad range of topics related to targeted therapies, including (but not limited to) novel targets, clinical and regulatory aspects of development, and investigation into drug resistance mechanisms and management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)